表紙
市場調查報告書

皮膚瘙癢治療藥的全球市場:2019年∼2023年

Global Pruritus Drugs Market 2019-2023

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 891083
出版日期 內容資訊 英文 143 Pages
訂單完成後即時交付
價格
Back to Top
皮膚瘙癢治療藥的全球市場:2019年∼2023年 Global Pruritus Drugs Market 2019-2023
出版日期: 2019年07月12日內容資訊: 英文 143 Pages
簡介

瘙癢症藥物用於治療與皮膚或全身性疾病相關的瘙癢。2018年,血液搔癢市場區隔最獲得了高市場佔有率,不過,腫瘤性搔癢市場區隔,由於引起搔癢的腫瘤學性前兆的增加,預計預測期間在市場佔有率處於領先地位。幾乎所有類型的癌症都使患者發生瘙癢的風險增加。還有全球搔癢治療藥市場,免疫療法偏好的高漲及慢性疾病的罹患率的上升等成為成長要素,預計在預測期間內將以5%以上的年複合成長率擴大。然而,替代療法的利用可能性,複雜的病因,及患者醫囑遵從性低,可能妨礙預測期間的搔癢治療藥產業的成長。

本報告提供全球皮膚瘙癢治療藥市場相關調查分析,市場規模及成長率,市場趨勢,市場的推動要素與課題,市場機會驗證,再加上主要供應商等相關的系統性資訊。

目錄

第1章 摘要整理

第2章 調查範圍

  • 簡介1
  • 簡介2
  • 美金的貨幣換算比率

第3章 市場情形

  • 市場生態系統
  • 市場特徵
  • 市場區隔分析

第4章 市場規模

  • 市場定義
  • 市場規模(2018年)
  • 市場規模及預測(2018年∼2023年)

第5章 波特的五力分析

  • 買主談判力
  • 供應商談判力
  • 新加入廠商的威脅
  • 替代品的威脅
  • 競爭對手的威脅
  • 市場情況

第6章 開發平台

第7章 市場區隔:各應用領域

  • 市場區隔:各應用領域
  • 各應用領域比較:市場規模及預測(2018年∼2023年)
  • 血液搔癢
  • 腫瘤性皮膚瘙癢
  • 腎皮膚瘙癢
  • 內分泌皮膚瘙癢
  • 膽汁搔癢
  • 市場機會:各應用領域

第8章 市場區隔:各給藥途徑

第9章 客戶形勢

第10章 各地區形勢

  • 各地區市場區隔
  • 各地區比較:市場規模及預測(2018年∼2023年)
  • 北美
  • 歐洲
  • 亞洲
  • 其他地區
  • 主要國家
  • 市場機會

第11章 決策架構

第12章 成長要素與課題

  • 市場成長要素
  • 市場課題

第13章 市場趨勢

第14章 業者情勢

  • 概要
  • 創造性破壞狀況
  • 競爭模式

第15章 供應商分析

  • 交易廠商
  • 供應商分類
  • 供應商的市場定位
  • Allergan Plc
  • Astellas Pharma Inc.
  • GlaxoSmithKline Plc
  • Pfizer Inc.
  • Sanofi

第16章 附錄

  • 調查方法
  • 簡稱的清單
  • 供應商的市場定位定義

第17章 關於TECHNAVIO

目錄
Product Code: IRTNTR31704

About this market

Pruritus drugs are used to treat itches associated with skin or systemic diseases. Technavio's pruritus drugs market analysis considers sales from the topical, oral, and parenteral segments. The market is also segmented based on application into hematologic pruritus, oncological pruritus, renal pruritus, endocrine pruritus, and cholestatic pruritus. Our analysis also considers the sales of pruritus drugs in Asia, Europe, North America, and ROW. In 2018, the hematologic pruritus segment held the highest market share. However, the oncological pruritus segment will lead in terms of market share over the forecast period owing to rising oncological indications that cause pruritus. Almost all types of cancers put patients at increased risk of developing pruritus. Also, our global pruritus drugs report has observed market growth factors such as the growing preference for immunotherapy and rising prevalence of chronic diseases. However, the availability of alternative therapies, complex pathogenesis, and poor patient adherence may hamper the growth of the pruritus drugs industry over the forecast period.

Overview

Growing preference for immunotherapy

The rising use of immunotherapy drugs to treat oncological indications is increasing the incidence of pruritus. As a result, the demand for pruritus drugs such as topical emollients, antihistamines, and topical corticosteroids is increasing. The high efficacy of immunotherapy in treat cancer is not allowing patients to withdraw from the treat. Therefore, the growing preference for immunotherapy will help market vendors in increasing sales. This will contribute to the growth of the global pruritus drugs market at over 5% CAGR during the forecast period.

Nanoparticle-enabled transdermal drug delivery systems

Transdermal drug delivery is not effective in the delivery of small and lipophilic drugs. As a result, vendors have come up with nanoparticle-enabled transdermal drug delivery systems, which provide faster onset of action. They are also less painful compared with routes that require incisions. Moreover, biodegradable nanoparticles can prolong the duration of drug adhesion. These factors will increase the adoption of nanoparticle-enabled transdermal drug delivery systems, which will have a positive impact on the overall market growth.

For the detailed list of factors that will drive the global pruritus drugs market during the forecast period 2019-2023, view our report.

Competitive Landscape

With the presence of several major players, the global pruritus drugs market is fragmented. Technavio's robust vendor analysis is designed to help clients in improving their market positions, and in line with this, this report provides a detailed analysis of several leading Pruritus Drugs manufacturers, which include Allergan Plc, Astellas Pharma Inc., GlaxoSmithKline Plc, Pfizer Inc., and Sanofi.

Also, the pruritus drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: PIPELINE

PART 07: MARKET SEGMENTATION BY APPLICATION

  • Market segmentation by application
  • Comparison by application
  • Hematologic pruritus - Market size and forecast 2018-2023
  • Oncological pruritus - Market size and forecast 2018-2023
  • Renal pruritus - Market size and forecast 2018-2023
  • Endocrine pruritus - Market size and forecast 2018-2023
  • Cholestatic pruritus - Market size and forecast 2018-2023
  • Market opportunity by application

PART 08: MARKET SEGMENTATION BY ROA

PART 09: CUSTOMER LANDSCAPE

PART 10: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 11: DECISION FRAMEWORK

PART 12: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 13: MARKET TRENDS

PART 14: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 15: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Allergan Plc
  • Astellas Pharma Inc.
  • GlaxoSmithKline Plc
  • Pfizer Inc.
  • Sanofi

PART 16: APPENDIX

  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors

PART 17: EXPLORE TECHNAVIO

List of Exhibits

  • Exhibit 01: Product overview
  • Exhibit 02: Global pharmaceuticals market
  • Exhibit 03: Segments of global pharmaceuticals market
  • Exhibit 04: Market characteristics
  • Exhibit 05: Market segments
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2018
  • Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 10: Five forces analysis 2018
  • Exhibit 11: Five forces analysis 2023
  • Exhibit 12: Bargaining power of buyers
  • Exhibit 13: Bargaining power of suppliers
  • Exhibit 14: Threat of new entrants
  • Exhibit 15: Threat of substitutes
  • Exhibit 16: Threat of rivalry
  • Exhibit 17: Market condition - Five forces 2018
  • Exhibit 18: Global pruritus drugs market pipeline: Overview
  • Exhibit 19: Global pruritus drugs market pipeline: Snapshot
  • Exhibit 20: Application - Market share 2018-2023 (%)
  • Exhibit 21: Comparison by application
  • Exhibit 22: Hematologic pruritus - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 23: Hematologic pruritus - Year-over-year growth 2019-2023 (%)
  • Exhibit 24: Oncological pruritus - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 25: Oncological pruritus - Year-over-year growth 2019-2023 (%)
  • Exhibit 26: Renal pruritus - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 27: Renal pruritus - Year-over-year growth 2019-2023 (%)
  • Exhibit 28: Endocrine pruritus - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 29: Endocrine pruritus - Year-over-year growth 2019-2023 (%)
  • Exhibit 30: Cholestatic pruritus - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 31: Cholestatic pruritus - Year-over-year growth 2019-2023 (%)
  • Exhibit 32: Market opportunity by application
  • Exhibit 33: RoA - Market share
  • Exhibit 34: Few prominent topical drugs
  • Exhibit 35: Customer landscape
  • Exhibit 36: Market share by geography 2018-2023 (%)
  • Exhibit 37: Geographic comparison
  • Exhibit 38: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 39: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 40: Top 3 countries in North America
  • Exhibit 41: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 42: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 43: Top 3 countries in Europe
  • Exhibit 44: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 45: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 46: Top 3 countries in Asia
  • Exhibit 47: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 48: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 49: Top 3 countries in ROW
  • Exhibit 50: Key leading countries
  • Exhibit 51: Market opportunity
  • Exhibit 52: Indications that are associated with pruritus
  • Exhibit 53: Impact of drivers and challenges
  • Exhibit 54: Vendor landscape
  • Exhibit 55: Landscape disruption
  • Exhibit 56: Vendors covered
  • Exhibit 57: Vendor classification
  • Exhibit 58: Market positioning of vendors
  • Exhibit 59: Allergan Plc - Vendor overview
  • Exhibit 60: Allergan Plc - Business segments
  • Exhibit 61: Allergan Plc - Organizational developments
  • Exhibit 62: Allergan Plc - Geographic focus
  • Exhibit 63: Allergan Plc - Segment focus
  • Exhibit 64: Allergan Plc - Key offerings
  • Exhibit 65: Allergan Plc - Key customers
  • Exhibit 66: Astellas Pharma Inc. - Vendor overview
  • Exhibit 67: Astellas Pharma Inc. - Business segments
  • Exhibit 68: Astellas Pharma Inc. - Organizational developments
  • Exhibit 69: Astellas Pharma Inc. - Geographic focus
  • Exhibit 70: Astellas Pharma Inc. - Key offerings
  • Exhibit 71: Astellas Pharma Inc. - Key customers
  • Exhibit 72: GlaxoSmithKline Plc - Vendor overview
  • Exhibit 73: GlaxoSmithKline Plc - Business segments
  • Exhibit 74: GlaxoSmithKline Plc - Organizational developments
  • Exhibit 75: GlaxoSmithKline Plc - Geographic focus
  • Exhibit 76: GlaxoSmithKline Plc - Segment focus
  • Exhibit 77: GlaxoSmithKline Plc - Key offerings
  • Exhibit 78: GlaxoSmithKline Plc - Key customers
  • Exhibit 79: Pfizer Inc. - Vendor overview
  • Exhibit 80: Pfizer Inc. - Business segments
  • Exhibit 81: Pfizer Inc. - Organizational developments
  • Exhibit 82: Pfizer Inc. - Geographic focus
  • Exhibit 83: Pfizer Inc. - Segment focus
  • Exhibit 84: Pfizer Inc. - Key offerings
  • Exhibit 85: Pfizer Inc. - Key customers
  • Exhibit 86: Sanofi - Vendor overview
  • Exhibit 87: Sanofi - Business segments
  • Exhibit 88: Sanofi - Organizational developments
  • Exhibit 89: Sanofi - Geographic focus
  • Exhibit 90: Sanofi - Segment focus
  • Exhibit 91: Sanofi - Key offerings
  • Exhibit 92: Sanofi - Key customers
  • Exhibit 93: Validation techniques employed for market sizing
  • Exhibit 94: Definition of market positioning of vendors
Back to Top